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Abstract
Multiple sclerosis (MS) is a neuroinflammatory disease with a relapsing-remitting disease course 
at early stages, distinct lesion characteristics in cortical gray versus subcortical white matter, and 
neurodegeneration at chronic stages. We assessed multilineage cell expression changes using 
single-nucleus RNA sequencing (snRNA-seq) and validated results using multiplex in situ 
hybridization in MS lesions. We found selective vulnerability and loss of excitatory CUX2-
expressing projection neurons in upper cortical layers underlying meningeal inflammation; such 
MS neuron populations showed upregulation of stress pathway genes and long non-coding RNAs. 
Signatures of stressed oligodendrocytes, reactive astrocytes and activated phagocytosing cells 
mapped most strongly to the rim of MS plaques. Interestingly, snRNA-seq identified 
phagocytosing microglia and/or macrophages by their ingestion and perinuclear import of myelin 
transcripts, confirmed by functional mouse and human culture assays. Our findings indicate 
lineage- and region-specific transcriptomic changes associated with selective cortical neuron 
damage and glial activation contributing to MS lesion progression.
Multiple sclerosis (MS) is a progressive neuroinflammatory autoimmune disease affecting 
about 2.3 million people worldwide1. Immune-mediated cytotoxic damage to 
oligodendrocytes (OLs) causes demyelination and focal plaque formation2,3 accompanied 
by progressive axonal damage in white matter (WM)4,5, and active MS plaques typically 
show a rim of inflammation with myelin phagocytosis. MS lesion heterogeneity in WM 
versus gray matter (GM) compartments suggests that the underlying pathobiology and 
potential for repair is likely to vary in a region-restricted manner. Cortical GM pathologies 
include demyelination and damage to the axon, neurite and neuron cell body6, particularly 
in areas underlying meningeal inflammation with plasma cell infiltration7–9. However, 
whether this process affects all or a subset of cortical neurons is poorly understood10. 
Indeed, cell type-specific mechanisms of MS progression, including scar formation with 
slowly expanding WM lesions11 and cortical atrophy12 are unclear.
Single-cell transcriptomic techniques are well suited to identify cellular heterogeneity in the 
human brain; recently, they have been applied to individual glial lineages in MS13,14. Here, 
we took a multilineage approach to brain-resident populations (neurons, astrocytes, OLs, 
microglia) to better understand molecular, cellular and spatially-restricted substrates of 
progressive MS pathology. We used frozen human brain samples from MS cases and 
controls to perform unbiased isolation of nuclei from cortical and subcortical lesion and non-
lesion areas followed by single-nucleus RNA-sequencing (snRNA-seq)13,15 and in situ 
validation of RNA gene expression across large anatomical areas. Our results indicate that 
genes most dysregulated in MS map spatially to vulnerable upper cortical layer neurons and 
reactive glia at the borders of subcortical MS lesions associated with progression in MS
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Results
snRNA-seq using post-mortem frozen MS tissue reveals cell-type specific molecular 
changes associated with MS pathogenesis
We used snRNA-seq to profile cortical GM and adjacent subcortical WM MS lesion areas at 
various stages of inflammation and demyelination, and control tissue from unaffected 
individuals. We established a pipeline for serial sectioning of entire tissue blocks including 
lesion and non-lesion GM and WM areas plus meningeal tissue. Tissue sections were 
screened for RNA integrity number (RIN) of >6.5. Using this criterion, 12/19 MS tissue 
samples screened from 17 individuals and 9/16 samples screened from control individuals 
were further procesed (Fig. 1a; Supplementary Table 1). Confounding variables of age, sex, 
postmortem interval and RIN were not significantly different between control and MS 
subjects (p > 0.1, Mann-Whitney U test).
We optimized and performed unbiased nuclei isolation using sucrose-gradient 
ultracentrifugation (Extended Data Fig. 1a), followed by snRNA-barcoding (10x Genomics) 
and cDNA sequencing. After quality control filtering, snRNA-seq yielded 48,919 single-
nuclei profiles (Fig. 1b-c). We normalized data and applied several independent analysis 
techniques. As shown (Fig. 1c), unbiased clustering identified 22 cell clusters (n.b., none 
comprised nuclei captured from individual MS or control samples). We detected a median of 
1,400 genes and 2,400 transcripts per nucleus with higher numbers detected in neuronal 
versus glial populations (Extended Data Fig. 1b, Supplementary Table 2).
Next, we annotated cell clusters based on expression of lineage marker genes for excitatory 
and inhibitory cortical neurons, astrocytes, OL lineage cells and microglia, as well as 
smaller cell populations (Fig. 1d, Extended Data Fig. 1e, Supplementary Table 3)16. 
Neuronal subtype markers included excitatory neuron marker SCL17A7, upper layer marker 
CUX2, layer 4 marker RORB, deep layer marker TLE4, as well as interneuron (IN) marker 
GAD2 and subtype markers PVALB, SST, VIP and SV2C. Comparing normalized nuclei 
numbers from MS and controls (Supplementary Table 4), we observed a selective reduction 
of upper-layer excitatory projection neuron (EN-L2-3A/B) numbers in MS samples with 
cortical demyelination (Fig. 1e-f). In contrast, numbers of intermediate (EN-L4) and deep-
layer (EN-L5-6) excitatory neurons, THY1/NRGN-high-expressing pyramidal cells, VIP-
expressing, somatostatin (SST) - and parvalbumin (PVALB)-expressing INs were similar 
between MS samples and controls (Fig. 1e-f). MS-associated genes showed greatest 
differential expression in EN-L2-3, followed by EN-L4 and myelinating OLs (Fig. 1g). 
Notably, for EN-L2-3 and OLs, transcriptomic changes distinguished subclusters from MS 
or control samples (Fig. 1c and 1e). In contrast to EN-L2-3 cells, gene dysregulation was 
less pronounced in upper layer VIP-expressing INs (Fig. 1g). These findings suggested cell-
type vulnerability of layer 2/3 excitatory CUX2-expressing neurons.
Selective vulnerability of CUX2-expressing upper layer neurons in MS—We 
investigated changes in CUX2-expressing EN-L2-3 cells in MS lesion pathology using 
unsupervised pseudotime trajectory analysis to identify dynamic gene expression changes. 
As shown (Fig. 2a), cell distribution along the trajectory separated control from MS in EN-
L2-3 cells. Interestingly, progression along the trajectory correlated with conventional 
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inflammatory lesion staging and the degree of upper layer cortical demyelination (Fig. 2b, 
Extended Data Fig. 1c-d), e.g., CUX2-expressing neurons, which localized towards the 
trajectory end, derived mainly from samples harboring late chronic inactive lesions with 
extensive subpial demyelination versus lesions with less upper cortical demyelination (Fig. 
2c).
Trajectory analysis highlighted gene ontology (GO) terms and dynamic upregulation of 
oxidative stress, mitochondrial dysfunction and cell death pathways in EN-L2-3 cells, 
including FAIM2, ATF4, CLU, B2M (cell stress/death), HSPH1, HSP90AA1 (heat-shock 
response), APP, NEFL, UBB (protein accumulation, axon degradation), COX7C, PKM, 
PPIA (energy metabolism, oxidative stress) and long-noncoding (lnc) RNAs LINC00657 
(NORAD) and BCYRN1 (BC200) (Fig. 2d-e, Extended Data Fig. 2a, Supplementary Table 
5)17,18. Conversely, we noted dynamic downregulation of transcripts associated with 
mitochondrial energy consumption (FARS2), glutamate signaling (GRIA4, GRM5), 
potassium/cation homeostasis (KCNB2, KCNN2, SLC22A10), neuronal signaling (NELL1), 
axon plasticity (ROBO1) and lncRNA LINC01266 (Fig. 2f). Neurons from all cortical layers 
in MS showed enrichment of cell stress pathways compared to controls (Extended Data Fig. 
2b, Supplementary Table 6); in contrast, PVALB- and VIP-expressing INs showed only one 
GO term (associated with protein folding) enriched for dysregulated genes. Together, these 
findings highlighted a selective transcriptomic damage signature for CUX2-expressing 
neurons in MS.
Loss of CUX2-expressing neurons in demyelinated cortical MS lesions in situ
—We next used large area spatial transcriptomic (‘LaST’) mapping19 to validate cell type-
specific gene expression changes. We optimized chromogenic and multiplex small molecule 
fluorescent in situ hybridization (smFISH) protocols to overcome high levels of background 
auto-fluorescence in WM and GM areas in frozen human brain samples. As shown (Fig. 3a), 
we achieved a favorable signal-to-noise ratio over tissue sections for neuronal markers 
CUX2 and SYT1 combined with immunohistochemistry for myelin oligodendrocyte 
glycoprotein (MOG), and we confirmed layer-associated expression of neuronal subtype 
markers RORB, THY1, TLE4, VIP and SST (Fig. 3a, Extended Data Fig. 3a).
Given snRNA-seq findings above, we investigated expression of co-located upper layer 
CUX2- and VIP-expressing populations by smFISH in MS and control sections (Fig. 3b). 
We found a significant reduction of CUX2-expressing neurons in completely and 
incompletely demyelinated cortical areas; in contrast, numbers of abutting VIP-expressing 
INs were maintained. Of note, meningeal infiltration of IGHG1/ MZB1-expressing plasma 
cells (that predominated over SKAP1+ T cells) was a common finding in sulci with 
underlying upper cortical layer demyelination and loss of CUX2-expressing neurons 
(Extended Data Fig. 3b)7,20.
We next used smFISH to validate upregulation of the cell stress markers, including PPIA 
(encoding prolyl isomerase cyclophilin A, Extended Data Fig. 2a) in MS EN-L2-3 and EN-
L4 neurons. As shown (Fig. 3c), PPIA transcripts were increased in neurons from 
demyelinated and adjacent normal-appearing cortical lesion areas21. We confirmed 
upregulated NORAD in EN-L2-3 and EN-L4 neurons (Extended Data Fig. 2a) by 
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chromogenic and fluorescent smFISH, and observed cytoplasmic NORAD accumulation in 
MS lesions as compared to normal-appearing areas with intact myelin (Fig. 3c). Together, 
these findings confirm degeneration and selective loss of CUX2-expressing upper layer 
excitatory neurons in cortical MS lesions, while co-located inhibitory and other cortical 
excitatory neuron subtypes were relatively preserved.
Distinct spatial macroglial signatures in cortical and subcortical MS lesions—
Prior studies have indicated differential gene expression and functionally diverse properties 
of reactive astrocytes that can be antagonistic or beneficial to repair after injury22,23. We 
identified astrogliosis by enhanced immunoreactivity for glial fibrillary acidic protein 
(GFAP) in regions of subcortical demyelinated WM that did not cross into the demyelinated 
cortex in MS lesions (Extended Data Fig. 4a). The GFAP signature in demyelinated WM 
overlapped with CD44-expressing reactive astrocytes24; CD44 showed upregulation at the 
lesion rim in astrocytes that co-expressed CRYAB and MT3 (Extended Data Fig. 4a-b)25. 
As shown (Fig. 4a, Extended Data Fig. 4a), RFX4 expression was specific to the astrocyte 
lineage and captured all SLC1A2-positive GM and CD44-expressing WM astrocytes 
(Supplementary Table 3, Extended Data Fig. 4a). We observed downregulation of genes for 
glutamate (SLC1A2, GLUL) and potassium homeostasis (KCNJ10)26 in cortical GM 
astrocytes and confirmed expression of GPC5, a marker that co-localizes with RFX4-
expressing GM astrocytes, in lesion and non-lesion cortical areas in situ (Fig. 4a-b, Extended 
Data Fig. 4a). Reactive astrocytes at inflammatory chronic active lesion rims showed strong 
expression of the transcription factors BCL6, FOS (encoding c-FOS) – associated with 
astrocyte endothelin receptor type B (EDNRB) upregulation – and LINC01088 (Fig. 4b, 
Extended Data Fig. 4b)27. Thus, spatial transcriptomics revealed distinct expression patterns 
for cortical versus subcortical reactive astrocytes in the MS lesion microenvironment.
Myelinating OLs characterized by myelin gene expression and the transcription factor ST18 
(Fig. 1d, Extended Data Fig. 4c) exhibited the third highest number of differentially 
expressed genes (Fig. 1g) consistent with enriched stress pathways (Extended Data Fig. 4d) 
and known cell loss in MS. Differential gene expression analysis indicated upregulation of 
genes for heat shock response (HSP90AA1) (Extended Data Fig. 4e)34, cell stress (FAIM2, 
ATF4), MHC class I upregulation (B2M, HLA-C), iron accumulation (FTL, FTH1)28, 
ubiquitin-mediated protein degradation (UBB) and LINC00657 (NORAD) and LINC00844 
(Fig. 4c-d, Extended Data Fig. 2a). Conversely, we observed downregulation of markers for 
OL differentiation and myelin synthesis (BCAS1, SGMS1)29, potassium/cation homeostasis 
(KCNJ10)26, cell-cell-interaction (SEMA6A) and formation of the node of Ranvier 
(GLDN) in MS OLs at lesion borders (Fig. 4c). Our findings indicate severe cell stress in 
MS OLs that can be mapped back to periplaque rim areas of subcortical lesions.
Activated phagocytosing microglial cells can be identified by snRNA-seq and 
mapped to chronic-active MS lesion rims—Given dramatic expansion of microglia in 
MS samples (Fig. 1e), we performed hierarchical clustering (Extended Data Fig. 5) and 
observed microglial cells with a homeostatic gene expression signature (P2RY12, RUNX1, 
CSF1R) in MS and control samples as well as MS-specific cells with enrichment for 
transcripts encoding activation markers, complement factors and MHC-II associated 
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proteins14, and lipid degradation (ASAH1, ACSL1, DPYD) (Fig. 5a-b, Extended Data Fig. 
5, Supplementary Table S5). Downregulated genes in MS microglia included synapse 
remodeling transcript SYNDIG1 and potassium channel KCNQ3. As shown (Fig. 5a-b), 
marker genes for microglia reactivity (CD68, CD74, FTL, MSR1) colocalized with the 
lineage microglia marker RUNX1, and mapped such activated cells to chronic active 
boundaries of subcortical MS lesions.
Interestingly, we found a cluster of microglial cells characterized by phagocytosis and 
enrichment for OL-specific markers PLP1, MBP and ST18 (Fig. 1c-d, Extended Data Fig. 
4c and 5, Supplementary Table 7) suggesting the possibility that ingested myelin transcripts 
co-purified with nuclei of phagocytosing cells in MS. To provide functional evidence for 
putative myelin RNA microglial phagocytosis, we cultured human and mouse microglia 
exposed to purified myelin from rat brain (Fig. 5c), which contains myelin transcripts 
(Extended Data Fig. 6)30. As shown (Fig. 5c), PLP1 and MBP transcripts were observed in 
intracellular, perinuclear and nuclear compartments of cultured human or mouse microglia at 
1-day post exposure to labeled (pHrodo) myelin; ingested MBP mRNA was observed in 
mouse microglia up to 4-days post-feeding. In parallel, we observed morphological changes 
in phagocytosing mouse microglia, differential upregulation of the activation marker Cd163 
and downregulation of the homeostatic microglia marker P2ry1231. Such changes in mouse 
microglia showed parallel gene expression changes in human MS microglia by snRNA-seq 
(Fig. 5c).
Interactive single-cell web browser to visualize snRNA-seq data
We created an interactive web browser to analyze cell-type specific expression levels of 
genes and transcriptomic changes in MS versus control tissue (https://ms.cells.ucsc.edu).
Discussion
MS lesions are heterogeneous in cortical and subcortical areas with distinct patterns of 
inflammatory demyelination10,32,33. We found cell type-specific gene expression changes 
in regions of cortical neurodegeneration and at the rim of chronic active subcortical lesions 
involved in progression and cortical atrophy. Our technical finding of snRNA-seq feasibility 
in MS is consistent with recent observations13–15. We used high-quality archival samples 
from patients, who did not receive modern immunomodulatory therapies; thus, they 
represent the endpoint of the natural disease course with relatively early death of patients 
(30-50 yrs). However, the number of MS samples studied could have resulted in under-
reporting of certain lineages.
Computational analysis of differential gene expression and trajectory analysis of a total of 
12 MS and 9 control samples pointed most strongly to the neuronal compartment and 
indicated dramatic cellular stress and loss of CUX2-expressing upper layer excitatory 
projection neurons in demyelinated and partially remyelinated cortical MS lesions. As such 
lesions underlie meningeal inflammation with pronounced plasma B cell infiltration, these 
findings suggest the importance of B cells in progressive MS7,8 and that damaged cortical 
neuron populations potentially benefited from B cell depleting therapies34.
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We validated candidate gene expression using spatial transcriptomics of human MS brain. 
Markers of stressed CUX2-expressing neurons included PPIA (cyclophilin A) and NORAD, 
a neuronal lncRNA that helps stabilize DNA upon genomic stress by binding to PUMILIO 
and RBMX proteins 17,35, as well as other pathways for protein degradation, heat shock 
response and metabolic exhaustion36,37. Whereas most transcriptional changes and 
neuronal cell loss occurred in demyelinated regions, we also observed abnormal gene 
expression features (e.g., PPIA) in normal-appearing cortical areas suggesting a gradient of 
pathology38. While it is possible that CUX2-expressing projection neurons are damaged by 
both sustained meningeal inflammation and retrograde axon pathology from juxtacortical 
WM lesions in MS33, additional intrinsic factors might account for their lack of resilience, 
especially considering that neighboring inhibitory and excitatory neurons of the cortex 
showed relatively little cell loss.
Recent studies used MS WM lesion single-nuclei and single-cell RNA-seq to study the 
OL13 and microglia14 lineages and reported subsets linked to MS pathobiology. Here, we 
used spatial transcriptomics to map dysregulated glial gene expression in cortical and 
subcortical lesion and non-lesion areas. Transcriptomic changes associated with OL, 
microglia and astrocyte activation mapped predominantly to the rim areas of chronic active 
subcortical lesions11,39. In particular, lesion rim OLs28 showed molecular changes 
indicating cellular degeneration and iron overload. Notably, both stressed myelinating OLs 
and upper layer cortical projection neurons upregulated genes for self-antigen presentation 
to immune cells (B2M, HLA-C) suggesting processes perpetuate degeneration and 
inflammation40,41.
In another example of spatial diversity in MS, we detected distinct transcripts for cortical 
versus subcortical lesion astrocytes, indicating molecular differences in the tissue 
microenvironment. Further, we found that snRNA-seq can distinguish phagocytosing cells in 
MS based on their transport of ingested myelin transcripts into peri-nuclear structures or the 
nucleus itself. Future work is needed to determine whether this biology is beneficial or 
detrimental in disease course, e.g., by exacerbating inflammation. In summary, multilineage 
and spatial gene expression analysis indicates cell type-specific neuron vulnerability and 
glial activation patterns relevant to neurodegeneration and MS lesion progression.
Methods
Human tissue samples, ethical compliance and clinical information
All tissue included in this study was provided by the UK Multiple Sclerosis Tissue Bank at 
Imperial College, London, UK and the University of Maryland Brain Bank through the NIH 
NeuroBioBank. Human MS and control tissues were obtained via a prospective donor 
scheme following ethical approval by the National Research Ethics Committee in the UK 
(08/MRE09/31). We have complied with all relevant ethical regulations regarding the use of 
human postmortem tissue samples. We examined a total of 35 (19 MS and 16 controls) snap-
frozen brain tissue blocks obtained at autopsies from 17 MS patients and 16 controls.
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RNA extraction and integrity measurements
Frozen brain tissue samples encompassing the entire span of cortical GM with attached 
meninges and underlying subcortical WM were sectioned on a CM3050S cryostat (Leica 
Microsystems) to collect 100 μm-thick sections for total RNA and nuclei isolation. Total 
RNA from 10 mg tissue was isolated using Trizol (Invitrogen) and purified using the 
RNAeasy Kit (Qiagen) according to manufacturer’s instructions. Next, we performed RNA 
integrity analysis on the Agilent 2100 Bioanalyzer using the RNA 6000 Pico Kit (Agilent, 
5067-1514). Only samples with an RNA integrity number (RIN) ≥ 6.5 were used to perform 
nuclei isolation followed by snRNA-seq as samples with lower RIN generated low quality 
data. As the result, we excluded 14 samples (7 MS and 7 control samples) and performed 
snRNA-seq on total of 12 snap-frozen brain tissue blocks obtained at autopsies from 7 
female and 3 male MS patients (1 primary progressive MS, 9 secondary progressive MS; 
Supplementary table 1). The age of the MS patients ranged from 34 to 55 years (median 46 
years), and the disease duration from 5 to 43 years (median 18 years). For control tissue, we 
included a total 9 snap-frozen brain tissue blocks obtained at autopsies from 4 female and 5 
male individuals. The age of control patients ranged from 35 to 82 years (median 54 years; 
Supplementary table 1).
Nuclei isolation and snRNA-seq on the 10X Genomics platform
Control and MS samples were processed in the same nuclei isolation batch to minimize 
potential batch effects. 40 mg of sectioned brain tissue was homogenized in 5 mL of 
RNAse-free lysis buffer (0.32M sucrose, 5 mM CaCl2, 3 mM MgAc2, 0.1 mM EDTA, 10 
mM Tris-HCl pH 8, 1 mM DTT, 0.1% Triton X-100 in DEPC-treated water) using a glass 
Dounce homogenizer (Thomas Scientific) on ice42. The homogenate was loaded into a 30 
ml thick polycarbonate ultracentrifuge tube (Beckman Coulter). 9 ml of sucrose solution 
(1.8 M sucrose, 3 mM MgAc2, 1 mM DTT, 10 mM Tris-HCl in DEPC-treated water) was 
added to the bottom of the tube under the homogenate and centrifuged at 107,000 g for 2.5 
hours at 4°C. Supernatant was aspirated, and nuclei pellet was incubated in 250 μL of 
DEPC-treated water-based PBS for 20 min on ice before resuspending the pellet. Nuclei 
suspension were analyzed for the presence of debris, nuclei were counted using a 
hemocytometer and diluted to 2,000 nuclei/μL before performing single-nuclei capture using 
the 10X Genomics Single-Cell 3’ system (Extended Data Fig. 1a). Target capture of 4,000 
nuclei per sample was used. Control and MS samples were loaded on the same 10X chip to 
minimize potential batch effects. Single-nuclei libraries from individual samples were pulled 
and sequenced on the Illumina HiSeq 2500 machine. 10X nuclei capture and library 
preparation protocol was carried out according to the manufacturer’s recommendation 
without modification.
snRNA-seq data processing with 10X Genomics CellRanger software and data filtering
For library demultiplexing, fastq file generation, read alignment and unique molecular 
identifier (UMI) quantification, CellRanger software v 1.3.1 was used. CellRanger was used 
with default parameters, except for using pre-mRNA reference file (ENSEMBL GRCh38) to 
insure capturing intronic reads originating from pre-mRNA transcripts abundant in the 
nuclear fraction.
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Individual expression matrices containing numbers of UMIs per gene in each nucleus were 
filtered to retain nuclei with at least 500 genes and 1000 transcripts expressed. Genes 
expressed in less than three nuclei were filtered out. Mitochondrial RNA genes were filtered 
out as well to exclude transcripts originating from outside the nucleus and avoid biases 
introduced by nuclei isolation and ultracentrifugation. Individual matrices were combined, 
UMIs were normalized to the total UMIs per nucleus and log-transformed.
Dimensionality reduction, clustering and t-SNE visualization
A filtered log-transformed UMI matrix containing genes expressed in more than five cells 
was used to perform truncated singular value decomposition (SVD) with k=50. A screen plot 
was generated to select the numbers of significant principle components (PCs) by localizing 
the last PC before the explained variance reaches plateau. This resulted in selection of 11 
PCs. The significant PCs were used to calculate Jaccard distance-weighted nearest neighbor 
distances; number of nearest neighbors was assigned to root square of number of nuclei. The 
resulting graph with Jaccard-weighted edges was used to perform Louvain clustering43. To 
visualize nuclei transcriptomic profiles in two-dimensional space, t-distributed stochastic 
neighbor embedding (t-SNE) was performed44. Several original clusters expressed a 
combination of cell type markers, including interneuron subtypes, T cells, B cells, stromal 
cells and endothelial cells. These clusters were further subclustered by repeating PCA 
analysis of selected cell populations and performing partitioning around medoids (PAM) bi-
clustering (Supplementary table 2).
Cell type annotation
Cell types were annotated based on the expression of known marker genes visualized by t-
SNE plot, as well as by performing unbiased gene marker analysis (Supplementary table 3). 
For the latter, MAST was used to perform differential gene expression analysis by 
comparing nuclei in each cluster to the rest of nuclei profiles. Genes with a false discovery 
rate (FDR) <0.05 and at least two-fold gene expression upregulation were selected as cell 
type markers. Subtypes of projection neurons and interneurons were annotated based on 
combinatorial expression of inhibitory and excitatory markers and projection neurons and 
interneuron subtype markers.
Quantification of number of cell for cell types in MS and control samples
To get insight into enrichment or depletion of cell types in MS, numbers of nuclei in each 
cluster and individual were normalized to the total number of nuclei captured from each 
individual. The following formula was used:
Normalization factor = N(total nuclei in sample)/N(total nuclei in sample with largest number of total nuclei
captured)
Normalized cell number = N(raw cell number in a cell types captured from a sample)/Normalization factor
Then, normalized cell numbers in each sample and cell type were compared between MS 
and control groups using Mann-Whitney test (Supplementary Table 4).
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Differential gene expression analysis based on repeated down sampling
To estimate the degree of disease affection for different CNS cell types, the number of 
differentially expressed genes (DEG) between MS patients and controls was used as a 
surrogate parameter. We reasoned that the power to identify DEG is partially dependent on 
the number of cells detected in each cluster. Thus, we devised an analytical approach that 
corrects for cell count based on repeated down sampling to identical cell numbers for each 
donor-cluster combination. Specifically, 100 iterations of down sampling were performed, 
where 20 cells were randomly drawn from each donor for each cluster and combined into 
synthetic bulk samples as input for a differential gene expression analysis using DESeq2 
version 1.20.045. In this case we favored a computationally less intensive analysis using 
DESeq2 without covariates on synthetic bulk samples over MAST to facilitate the execution 
of a sufficient number of iterations. The results of this screening approach were plotted as 
notched box plots and relevant differences between clusters were assumed where notches did 
not overlap (Fig. 1g). Notably, very small clusters which had less than 4 samples with a 
minimum of 20 cells available, were excluded from the analysis.
Trajectory pseudotime analysis
A single cell trajectory for excitatory cortical layer 2-3 neurons was determined and 
analyzed using the Monocle package version 3 alpha46. FDR-corrected p values were 
calculated using the Monocle 3alpha R package using 5,938 EN-L2-3 nuclei 
(Supplementary Table 5). Briefly, single cell transcriptomes of all CUX2-expressing cells 
were dimensionally reduced by principal component analysis (PCA) followed by uniform 
manifold approximation and projection (UMAP). Next, an unsupervised trajectory through 
the reduced space was identified using the SimplePPT algorithm. The root of the resulting 
tree was set to where most cells of the control samples clustered. Pseudotime values were 
then automatically assigned to each cell depending on its distance on the trajectory relative 
to the root node. Moran’s I test as implemented in Monocle 3 alpha was used to identify 
genes significantly regulated over pseudotime. For each gene the adjusted p value was 
signed by the direction of regulation determined by comparing expression in the first 5% of 
cells in pseudotime with the last 5%. The resulting gene list, ordered by signed adjusted p 
value, was the input for Gene Set Enrichment Analysis (GSEA) to test for enriched gene 
ontology (GO) terms using the clusterProfiler package version 3.10.147. Gene sets with a 
FDR < 0.05 were considered as significantly enriched. The results of the analysis were 
plotted as a GO term map using the emapplot() function of the clusterProfiler package to 
cluster terms based on their gene set relation. Clusters of gene sets were annotated with 
representative labels.
To analyze enrichment of individual gene sets on a single cell level, we employed the 
AUCell algorithm48. The algorithm measures geneset enrichment towards the top of an 
expression ranked gene list for each cell. The resulting area under the curve values (AUC) 
were plotted for all cells along pseudotime.
Differential gene expression analysis using linear mixed model regression
To identify genes differentially expressed in MS compared to control samples per cell type. 
P values were calculated and FDR-corrected using MAST R package. All nuclei from 9 
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control and 12 MS samples for corresponding cell types were used (Supplementary Table 6). 
MAST was used to perform zero-inflated regression analysis by fitting a linear mixed 
model. To exclude gene expression changes stemming from confounders, such as age, sex, 
RIN, cortical region, fractions of ribosomal and mitochondrial transcripts, 10X capture batch 
and sequencing batch, the following model was fit with MAST:
zlm(~diagnosis + sequencer + (1|ind) + cngeneson + age + sex + RIN + region + Capbatch + 
Seqbatch + ribo_perc + mito_perc, sca, method = "glmer", ebayes = F, silent=T)
Where cngeneson is gene detection rate (factor recommended in MAST tutorial), Capbatch 
is 10X capture batch, Seqbatch is sequencing batch, ind is individual label, ribo_perc is 
ribosomal RNA fraction and mito_perc is mitochondrial RNA fraction.
To identify genes differentially expressed due to the disease effect, likelihood ratio test 
(LRT) was performed by comparing the model with and without the diagnosis factor. Genes 
with at least 10% increase or decrease in expression in MS vs control and an FDR <0.05 
were selected as differentially expressed. In addition, we calculated raw fold changes of 
gene expression by repeating MAST analysis with only the diagnosis factor in the model and 
filtered out genes with raw fold change of expression less than 7%. The latter filtering step 
allowed removing genes, whose fold change of expression was heavily dependent on the 
confounding factors, rather than clinical diagnosis.
Gene Ontology (GO) analysis for differentially expressed genes
PANTHER software (Broad Institute, https://software.broadinstitute.org/panther) was used 
to perform statistical overrepresentation tests for DEGs with respect to individual clusters. 
All genes expressed in a given cluster were used as a background list, and GO term analysis 
for enriched biological processes was performed. Processes with an FDR < 0.05 were 
considered and sorted by FDR.
Heatmap data presentation and hierarchical cluster analysis
Hierarchical clustering was performed with the online Morpheus software (Broad Institute, 
https://software.broadinstitute.org/morpheus) using 1-Pearson correlation as distance metric 
and complete clustering of rows (genes) and columns (cells or samples). To perform 
hierarchical clustering, we used single-nuclei gene expression matrix of cell type markers 
for lymphocytes, microglia and phagocytes (Extended Data Fig. 5, Supplementary Table 7).
Immunohistochemistry
16 μm-cryosections were collected on superfrost slides (VWR) using a CM3050S cryostat 
(Leica Microsystems) and fixed in either 4% PFA at room temperature (RT) or ice-cold 
methanol. Next, sections were blocked in 0.1M PBS/0.1% Triton X-100/ 10% goat/horse/
donkey sera for 1 hour at RT. Primary antibody incubations were carried out overnight at 
4°C. The following antibodies were used for immunohistochemistry: mouse anti-MOG 
(clone 8-18C5, 1:1,000 [1:200 after in situ hybridization], Millipore Sigma), rat anti-GFAP 
(clone 2.2B10, 13-0300, Thermo Fisher, 1:1,000 [1:200 after in situ hybridization]), rat anti-
CD3 (clone CD3-12, Bio-Rad, 1:100), rabbit anti-MZB1 (polyclonal, Thermo Fisher, 
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1:1,000), rabbit anti-SKAP1 (polyclonal, Sigma Aldrich, 1:100), mouse anti-CD138 (clone 
DL-101, Biolegend, 1:100), mouse anti-CD68 (clone 514H12, Bio-Rad, 1:100), mouse anti-
Neurofilament H (NF-H), nonphosphorylated (clone SMI32, 801701, Biolegend, 1:10,000), 
mouse anti-NeuN (clone MAB377, Sigma Aldrich, 1:1,000). After washing in 0.1M PBS, 
cryosections were incubated with secondary antibodies diluted in 0.1M PSB/ 0.1% Triton 
X-100 for 2 hours, RT. For chromogenic assays, sections were incubated with biotinylated 
secondary IgG antibodies (1:500, Thermo Fisher) followed by avidin-biotin complex for 1-
hour incubation (1:500, Vector) and subsequent color revelation using diaminobenzidine 
according to the manufacturer’s recommendations (DAB, Dako). For immunofluorescence, 
Alexa fluochrome-tagged secondary IgG antibodies (1:500, Thermo Fisher) were used for 
primary antibody detection. Slides with fluorescent antibodies were mounted with DAPI 
Fluoromount-G (SouthernBiotech). Negative control sections without primary antibodies 
were processed in parallel. For diagnostic purposes, hematoxylin and eosin (HE) and Luxol 
fast blue (LFB) staining was carried out.
Iron staining
Tissue non-heme iron was stained according to previously published protocols49. Sections 
of fixed, frozen human tissue was allowed to warm to room temperature and dried for 15 
minutes in a laminar flow hood. Endogenous peroxidase activity was quenched by 
immersion in a solution of 0.3% H2O2 (v/v) in methanol for 20 minutes and washed three 
times in deionized water (dH2O). Sections were then placed in a solution of fresh 1% (w/v) 
potassium ferrocyanide (Sigma-Aldrich, UK), pH 1 with HCL for 40 minutes, followed by 
three washes in dH2O. Sections were then placed in 0.01M NaN3, 0.3% H2O2 in methanol 
for 60 minutes, followed by three washes in PBS. Iron staining was intensified using 3’-
diaminobenzidine (DAB) (10% v/v) solution from Pierce DAB substrate kit (Thermo Fisher) 
in PBS with 0.005% H2O2 (v/v) for five hours. DAB reaction was halted with three washes 
in PBS, 1 wash in 100% methanol and a further three washes in Bond Wash solution (Leica 
Biosystems).
Chromogenic single/duplex in situ RNA hybridization
Single molecule in situ hybridization was performed according to the manufacturer’s 
recommendations (RNAscope 2.5 brown, red and duplex chromogenic manual assay kits, 
Biotechne). Sequences of target probes, preamplifier, amplifier, and label probes are 
proprietary and commercially available (Advanced Cell Diagnostics). Typically, target 
probes contain 20 ZZ probe pairs (approx. 50 bp/pair) covering 1,000 bp. The following 
human manual RNAscope assay probes were used: CUX2, RORB, TLE4, THY1, VIP, SST, 
HSP90AA1, LINC00657, PPIA, FTL, B2M, PIEZO2, IGHG1, MSR1, LINC01088, GPC5, 
CD44, BCL6, FOS, EDNRB, ST18, RUNX1-C2, SLC1A2-C2, CD44-C2, RFX4-C2, 
PDGFRA-C2, SYT1-C2, PLP1-C2. Following red chromogenic single-molecule in situ 
hybridization, we performed immunohistochemistry using either chromogenic or 
fluorescence assays (see above). After duplex single molecule in situ hybridization we 
performed hematoxylin staining of nuclei.
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Fluorescence multiplex in situ RNA hybridization and human brain tissue optimization
For small molecule fluorescence in situ RNA hybridization (smFISH) on human brain 
cryosections performed on an automated BOND RX robotic stainer (Leica), the following 
procedure was used. Fresh snap frozen human brain tissue was cryosectioned and slides 
immediately stored at -80°C. Because human brain tissue often showed high levels of 
autofluorescence, several treatments were needed to minimize interference with FISH 
signals. Using spectral analysis, we identified sources of autofluorescence to be mainly 
lipofuscin in grey matter (emission wavelengths ~450-650nm) and collagen/elastin in white 
matter (emission wavelengths ~470-520nm). Initial experiments in fixed tissue also 
displayed low levels of formaldehyde-induced fluorescence in the green yellow spectra 
(~420-470nm); thus, sections of human brain tissue were not formaldehyde-fixed before 
storage. On the day of the experiment, with minimal exposure to (RT) air to keep oxidation 
of endogenous fluorescent proteins low, slides where directly transferred from -80°C into 
pre-chilled PFA 4% (methanol-free). Following 45 minutes incubation sections where 
immediately submerged in boiling citrate buffer (pH 3.0, Sigma) for 15 minutes to loosen up 
the recent crosslinking. Slides where then rinsed twice in PBS and dehydrated. To avoid 
interference of background fluorescence, experiments were designed so that low expressing 
probes were detected using fluorophores with low background, i.e., Opal 570, Opal 650. All 
samples in this study were treated in the same way regardless of disease/stage and age. The 
assay was then performed for 2-3 genes by FISH using the RNAScope LS Multiplex Assay 
(Biotechne).
Samples were initially permeabilized with heat and protease treatment to improve probe 
penetration and hybridization. For heat treatment, samples were incubated in BOND ER2 
buffer (pH 9.0, Leica) at 95°C for 10 minutes. For protease treatment, samples were 
incubated in ACD protease reagent at 42°C for 10 minutes. Prior to probe hybridization, 
samples were incubated in hydrogen peroxide for 10 minutes to inactivate endogenous 
peroxidases and ACD protease. Subsequently, samples were incubated in target z-probe 
mixtures (C1-C4) for 2 hours at 42°C. Each slide wash flushed three times in order to obtain 
optimal hybridization to transcripts. The following human RNAScope LS assay probes were 
used: SYT1, CUX2, LINC00657, B2M, CD74, RUNX1, RFX4, SLC1A2, CD44, PLP1, 
MBP.
Following hybridization, branched DNA amplification trees were built through sequential 
incubations in AMP1, AMP2 and AMP3 reagents for 15-30 minutes each at 42°C with LS 
Rinse buffer (Leica) high stringency washes between incubation steps. After amplification, 
probe channels were detected sequentially via HRP-TSA labeling. Here, samples were 
incubated in channel-specific HRP reagents for 15 minutes at 42°C, TSA fluorophores for 
30 minutes and HRP blocking reagent for 15 minutes at 42°C. Probes were labeled using 
Opal 520, 570 and 650 TSA fluorophores (Perkin Elmer, 1:300). Directly following FISH 
assay, localization of MOG myelin protein was performed by BOND RX assisted IHC, 
where samples were incubated with anti-MOG antibody in blocking solution for 1 hour 
(1:200). To develop the antibody signal, samples were incubated in donkey anti-mouse HRP 
(Abcam, ab205719, 1:500) for 1 hour, TSA-biotin (PE, NEL700A001KT, 1:200) for 10 
minutes and streptavidin-conjugated Alexa 700 (Sigma, 1:200) for 30 minutes.
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PCR for myelin and neuron transcripts from rat myelin preparations
RNA from myelin was purified using phenol-chloroform extraction by adding 100 μl of 
chloroform (Sigma Aldrich) to 500 μl of Tri-Reagent containing 50 μl of enriched rat CNS 
myelin. Samples were vortexed and centrifuged at 12,000 gmax for 15 minutes at 4°C. The 
upper aqueous phase was collected and an equal volume of 70% ethanol added and vortexed. 
RNA was purified using PureLink RNA Mini-Kit (Thermo Fisher) according to 
manufactures instructions. RNA was eluted with 30 μl of RNAse free water and 
concentration determined using a SPECTROStar Nano. cDNA was synthesized from 0.3 μg 
of RNA using SuperScript III (Thermo Fisher) according to manufactures instructions with 
or without inclusion of RT enzyme. PCRs for rat Mbp and synaptophysin (Syp) were 
performed using 20 μl of PCR MegaMix Blue (Client Life Science), 1 μl of cDNA and 0.5 μl 
of 10 μM forward (F) and reverse (R) primers in an ABI Veriti 96 Well thermal cycler 
(Thermo-Fisher) for 30 cycles at 950C, 720C and 540C:
Mbp-F: GTGGTATGTGAGCACAGGCT
Mbp-R: TAAAAGCACCTGCTCTGGGG
Syp-F: TGCCATCTTCGCCTTTGCTA
Syp-R: GCCTGTCTCCTTGAACACGA
Amplified products were loaded onto 1% E-Gel (Thermo-Fisher) according to manufactures 
instructions and imaged using E-Gel imager (Thermo-Fisher).
Western blot and Coomassie staining for myelin and neuron protein from rat myelin 
preparations
15-20 μg of protein were separated on 4-12% Bis-Tris NuPAGE gels (Thermo-Fisher) 
according to manufactures instructions. Gels were either stained for total protein using 0.3% 
w/v brilliant blue-G (Sigma) in 40% v/v methanol and 7% v/v glacial acetic acid overnight. 
Destaining was done with several washes in 40% v/v methanol and 7% v/v glacial acetic. 
For Western blotting, proteins in gels were transferred onto PVDF membranes (Millipore) 
using Bolt transfer buffer (Thermo-Fisher) for 1 hour at 15 V constant voltage. Membranes 
were blocked with Li-Cor Blocking Buffer (Li-Cor) for 1 hour at room temperature on a 
platform shaker. Membranes were incubated overnight in primary antibodies (1:2000 
dilution) rabbit-anti-Mbp or mouse-anti-Mog (Cell Signaling), rabbit-anti Neurofilament 
heavy or mouse anti-synaptophysin (Sigma) in 50% Li-Cor Blocking buffer in tris buffered 
saline with tween-20 (0.001% v/v) (TBS-T). Membranes were washed three times with 
TBS-T and Li-Cor 680-RD secondaries (1:5000) (Li-Cor) applied in 50% v/v Li-Cor 
Blocking Buffer in TBS-T for 1 hour at room temperature. Membranes were three times in 
TBS-T and imaged on a Li-Cor Odyssey (Li-Cor).
Myelin Enrichment assay and polymerase chain reaction
Myelin enrichment of adult rat CNS was performed according to Jahn et al.50. Unless 
otherwise stated all buffers were prepared in DEPC treated water and all procedures carried 
out at 4°C. Briefly, adult rats were perfused with saline and the brains rapidly dissected, 
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olfactory bulbs removed and kept on ice. Brains were cut into hemispheres, and one 
hemisphere was used for each preparation. Hemispheres were homogenized using a glass 
Dounce in 6 ml of 0.32 M sucrose prepared in DEPC treated water with HALT protease 
inhibitor cocktail without EDTA (Thermo Fisher). 1ml of homogenate was retained for 
further biochemical analysis and 6ml of homogenate loaded on top of 6ml of 0.85 M sucrose 
treated with DEPC with HALT protease inhibitors in 14ml thin walled centrifuge tubes 
(Beckman Coulter, UK). Samples were centrifuged at 75,000 gmax for 35 minutes at 4°C. 
The interface between 0.85 and 0.32 M sucrose was collected, resuspended in water and 
centrifuged at 75,000 gmax for 15 minutes at 4°C. The pellet was subjected to two rounds of 
osmotic shock by resuspension in water, left on ice for 10 min and centrifuged at 12,500 
gmax for 15 minutes at 4°C. The pellet was resuspended in 6 ml of 0.32M sucrose and 
overlaid on a bed of 0.85 M sucrose and centrifuged at 75,000 gmax for 35 minutes at 4°C. 
The purified myelin was collected from the 0.32M and 0.85M sucrose interface. The myelin 
was then washed in 10 ml of water and centrifuged at 75,000 gmax for 35 minutes at 4°C and 
resuspended in either 0.25 M bicarbonate pH 8.3 or Tris Buffered Saline (TBS) pH 7.4 to 
final volume of 400 μl. A 50 μl was retained and 500 μl of Tri-Reagent (Thermo Fisher) was 
added to preserve the RNA. Protein concentration was measured using Pierce-BCA Protein 
Assay (Thermo Fisher) according to manufactures instructions.
Animals used for myelin-microglia engulfment assays
Wildtype C57Bl/6J mice (stock #000664) were obtained from Jackson Laboratories (Bar 
Harbor, ME). All animal experiments were carried out at the animal facility at the University 
of Massachusetts Medical School and approved (#A-2496-17) by Animal Care and Use 
Committees (IACUC) and performed under NIH guidelines for proper animal welfare.
Purification and treatment of primary mouse microglia
Purified primary brain-derived microglia were obtained from mixed glial cultures by 
modified standard protocols as described before51. Briefly, cerebral cortices from male and 
female postnatal day 0.5 C57Bl/6J wildtype mice were dissected free of meninges, chopped 
into small pieces and mechanically dissociated until a single cell suspension was obtained. 
Cells were then seeded in 10 ml DMEM (Thermo Fisher) supplemented with 10% FBS (Life 
Technologies) and 1% penicillin-streptomycin (Life Technologies) at a density of one brain 
per 75cm2 flask, and cultured for 7 days at 37°C in humidified 5% CO2/95% air. By shaking 
the culture flasks for 3 hours at 180 rpm, loosely adhering microglia were detached. The 
suspended microglial cells were seeded onto glass coverslips at a density of 80.000 cells/
well in a 24-well plate and cultured overnight. 24 h prior to treatment cell culture medium 
was changed to neurobasal medium supplemented with 1x sodium pyruvate, 1x B27 (all 
from Thermo Fisher), 1x GlutaMAX, 1x penicillin-streptomycin (both from Life 
Technologies), 5 μg/ml insulin, 1x SATO, 5 μg/ml N-acetyl-L-cysteine, 40 ng/ml T3 (all 
from Sigma), and 10 ng/ml mouse macrophage colony stimulating factor (Shenandoah). 
Finally, microglia were treated with 6.45 μg purified myelin fraction from rat brain for 4 
hours, before myelin was removed and cells were fixed or harvested for analysis at the 
indicated time points. To visualize engulfment of myelin proteins into microglial lysosomes, 
myelin protein was labeled with pHrodo (Thermo Fisher) under RNase free conditions 
according to the manufacture’s recommendations prior to treatment.
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Mbp RNA hybridization on primary mouse microglia
RNA in situ hybridization was performed according to the manufacturer’s recommendations 
(ACDBio). Briefly, after treatment, cells were fixed with 4% PFA, dehydrated and stored at 
-20°C for up to 7 days before further use. Prior to RNA hybridization, cells were rehydrated, 
rinsed in PBS and treated with 1:15 diluted “Protease III” for 15 minutes at 40°C. Then, 
probes against Mbp (ACDBio) were added and incubated for 2 hours at 40°C. Subsequent 
amplification steps were performed according to the manufacturer’s instructions. To confirm 
specificity of RNA signals, some samples were treated with 10 mg/ml RNaseA (Thermo 
Fisher Scientific) for 1h at 37°C prior to incubation with probes. To immunostain samples 
following Mbp RNA hybridization, cells were washed in PBS, blocked in 2% normal goat 
serum supplemented with 0.01% TritonX-100 for 30 minutes and incubated with the 
following primary antibodies: rabbit polyclonal anti-Iba1 (Wako Chemicals) and rat 
monoclonal anti-CD68 (clone FA-11, AbD Serotec, MCA1957) (both 1:100). The following 
day, cells were incubated with appropriate Alexa-fluorophore-conjugated secondary 
antibodies (Thermo Fisher Scientific) and mounted with vectashield containing DAPI 
(Vector laboratories). Random 63x fields of all cultures were imaged using identical settings 
on a Zeiss Observer Spinning Disk Confocal microscope equipped with diode lasers 
(405nm, 488nm, 594nm, 647nm) and Zen Blue acquisition software (Zeiss). For unbiased 
quantification of Mbp puncta, signals were co-localized to Iba1+ microglia blind to 
treatment of the samples and the number of total puncta as well as signals associated with 
microglia nuclei (0.5μm distance from the nucleus) were determined using ImageJ (NIH). 
Moreover, 630x z-stacks were acquired with 35-50 steps at 0.22 μm spacing and processed 
in Imaris (Bitplane, Switzerland) to 3D surface render engulfed signals as previously 
described.
RNA isolation and quantitative reverse transcriptase polymerase chain reaction
Total RNA from microglia was extracted using TRIzol (Life Technologies) acco52rding to 
manufacturer’s recommendations. 500 ng total RNA samples were transcribed into cDNA 
using Power SYBR™ Green Cells-to-CT Kit (Thermo Fisher Technologies) according to 
manufacturer’s instructions. Relative Cd163 and P2ry12 expression was determined by 
quantitative polymerase chain reaction (qPCR) in relation to Gapdh housekeeping gene 
expression using the following forward (F) and reverse (R) primers:
Cd163-F: GGGTCATTCAGAGGCACACTG
Cd163-R: CTGGCTGTCCTGTCAAGGCT
P2ry12-F: GTTCTACGTGAAGGAGAGCA
P2ry12-R: CTACATTGGGGTCTCTTCGC
Gapdh-F: TGTCCGTCGTGGATCTGAC
Gapdh-R: CCTGCTTCACCACCTTCTTG
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Human tissue sampling for primary human microglia assays
Human brain tissue was obtained with informed consent under protocol REC 16/LO/2168 
approved by the NHS Health Research Authority. Adult human brain tissue was obtained 
from three biopsies (age 17, male, diffuse axonal injury, right frontal lobe; age 61, male, 
unruptured cerebral aneurysm, right gyrus rectus; age 70, male, normal pressure 
hydrocephalus, right parietal lobe) taken from the site of neurosurgery resection for the 
original clinical indication. Tissue was transferred to Hibernate A low fluorescence (HALF) 
supplemented with 1x SOS (Cell Guidance Systems), 2% Glutamax (Life Technologies), 1% 
P/S (Sigma), 0.1% BSA (Sigma), insulin (4g/ml, Sigma), pyruvate (220 g/ml, Gibco) and 
DNase 1 Type IV (40 g/ml, Sigma) on ice and transported to a dedicated BCL 2 laboratory.
Dissociation of human brain tissue and purification of human microglia
Brain tissue was mechanically digested in fresh ice-cold HALF supplemented with 1x SOS 
(Cell Guidance Systems), 2% Glutamax (Life Technologies), 1% P/S (Sigma), 0.1% BSA 
(Sigma), insulin (4g/ml, Sigma), pyruvate (220 g/ml, Gibco) and DNase 1 Type IV (40 g/ml, 
Sigma). The prepared mix was spun in HBSS+ (Life Technologies) at 300g for 5 mins and 
supernatant discarded. The digested tissue was rigorously triturated at 4°C and filtered 
through a 70μm nylon cell strainer (Falcon) to remove large cell debris and undigested 
tissue. Filtrate was spun in a 22% Percoll (Sigma) gradient with DMEM F12 (Sigma) at 
800g for 20 minutes. Supernatant was discarded and the pellet was re-suspended in ice cold 
supplemented HALF. The isolated cell suspension was incubated with anti-CD11b 
conjugated magnetic beads (Miltenyi) for 15 minutes at 4°C. Cells were washed twice with 
supplemented HALF and passed through an MS column (Miltenyi). Each sample was 
washed three time in the column and then extracted. Cells were plated in DMEM F12 with 
10% foetal bovine serum and 0.1% Macrophage colony-stimulating factor (M-CSF). Note 
that incubators for all cell culture incubators are regularly tested for mycoplasma 
contamination.
Mbp and Plp1 RNA hybridization on primary mouse microglia
Purified rat brain myelin extracts from three biological replicates were diluted to 1 mg/mL 
(total protein) in 0.1 M sodium bicarbonate buffer, pH 8.3 in a volume of 100 μl. The pH 
sensitive fluorescent dye succinimidyl ester known as pHrodoRed (Thermo Fisher) was 
added from a 10 mM stock in DMSO to a final of 100 μM to each myelin extract for 45 
minutes at room temperature. Samples were centrifuged for 30 minutes at 17,000x g at 4°C 
and the supernatant discarded. The labelled myelin pellets were resuspended in 100 μl of 0.1 
M sodium bicarbonate buffer, pH 8.3 to a final of 1mg/ml of protein and 1.5 μl added to 
wells of human microglia in 24 well glass bottom plate (Cellvis) for phagocytosis over 18 
hours. The next day, the cells were washed twice with PBS before fixation with 4% PFA at 
room temperature for 10 minutes and washing with PBS.
Cells were manually stained for RNA using RNAScope using a modified automated 
procedure for the Leica BOND RX (Leica). Fixed cells were washed twice with BOND 
wash solution (Leica) before antigen retrieval with BOND Epitope Retrieval Solution 2 
(Leica) at 95°C and allowed to cool to room temperature, and followed by three washes with 
BOND wash. Cells were permeabilized with 0.5x RNAScope 2.5 LS Protease III 
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(Biotechne) in PBS at 37°C for 5 min, followed by cold BOND wash (40°C) and then two 
more BOND washes at room temperature. Endogenous peroxidase activity was quenched 
with RNAScope 2.5 LS Hydrogen Peroxide (Biotechne) for 10 minutes and followed by two 
more BOND washes. RNAScope probes for mouse Mbp (Biotechne) and Plp-1 (Biotechne) 
were diluted 1:50 in C1 probe. Mbp and Plp-1 probes were amplified using sequential 
treatments with RNAScope LS Multiplex AMP 1, 2 and 3 (Biotechne) for 30 minutes at 
42°C with BOND washing and RNAScope 2.5 LS Rinse Reagent (Biotechne) for 5 minutes 
each between each amplification step. Probe channel C2 for Mbp was fluorescently 
developed using RNAScope Multiplex HRP-C2 (Biotechne) for 15 minutes at 42°C, 
followed by BOND washes and incubation with tyramide-conjugated Opal 520 dye at 1: 
2,500 (Perkin Elmer) for 30 minutes followed with two more BOND washes. Residual HRP 
activity was quenched with RNAScope LS Multiplex HRP Blocker (Biotechne) for 15 
minutes at 42°C, followed by BOND washes. Probe channel C3 for Plp-1 was developed as 
for C2 but using RNAScope LS Multiplex HRP-C3 (Biotechne) and Opal 650 dye at 1:2,500 
(Perkin Elmer, UK) and followed by RNAScope LS Multiplex HRP Blocker (Biotechne) 
with BOND washing. Staining of LMNA/C (Laminutes A/C) was done after RNAScope 
development by incubating cells with mouse anti-porcine Laminutes A/C antibody (Insight 
Biotechnology, UK) at 1:200 and rabbit anti-Iba1 biotin conjugated antibody at 1:200 for 60 
minutes at RT. Excess primary antibodies were washed away with BOND wash and cells 
incubated goat anti-mouse IgG2B AlexaFlour 350 at 1:500 and streptavidin-conjugated 
AlexaFlour 700 at 1:1,000 for 60 minutes at RT. Cells were wash three times in BOND wash 
and twice in PBS before imaging on an Operetta CLS (Perkin-Elmer) spinning disk confocal 
microscope.
Image acquisition and analysis of human IHC and ISH experiments
Bright field images were acquired on Zeiss Axio Imager 2 and Leica DMi8 microscopes 
equipped with Zeiss Axiocam 512 color and Leica DMC5400 cameras. Fluorescent images 
were taken using Leica TCS SP8 and TCS SPE laser confocal and DMi8 widefield 
(equipped with Leica DFC7000 GT camera) microscopes with either 10x, 20x, 40x or 63x 
objectives; all fluorescent confocal pictures are Z-stack images, unless stated otherwise. 
High-resolution FISH images of human tissue sections were acquired on a spinning disk 
Operetta CLS (Perkin Elmer) in confocal mode using a sCMOS camera and a 40X NA 1.1 
automated-water dispensing objective. The field-of-view was 320 x 320 μm and voxel size 
0.3 x 0.3 x 1 μm. Each field was imaged as a z-stack consisting of 20 to 30 planes with a 1 
μm step size. z-heights of tissue sections were manually identified by imaging DAPI on 
sample fields prior to tissue-wide scans. Each z-plane was imaged across 5 channels 
depending on the experiment with exposure between 60 and 120 ms at 90% LED power. 3D 
projections were generated using raw imaging data in Volocity 6.3 software (Perkin Elmer). 
Images were processed using Fiji ImageJ or Photoshop software (Adobe) and exported to 
Illustrator vector-based software (Adobe) for figure generation.
Statistical Analysis
Data are presented as mean ± standard error of mean (SEM). Analyses were performed 
using two-tailed parametric or non-parametric (Mann-Whitney, Kruskal-Wallis) t-tests for 
two groups and if applicable, one-way ANOVA with corresponding post-hoc tests for 
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multiple group comparisons. P values were designated as follows: *p ≤ 0.05, **p ≤ 0.01, 
*** p ≤ 0.001, **** p ≤ 0.0001. Analyses were performed using GraphPad Prism (GraphPad 
Software).
Extended Data
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Extended Data Fig. 1. Sample and disease contribution of cell types captured by snRNA-seq.
(a) Representative images selected from nuclei suspensions (ctrl, n=9; MS, n=12) after 
ultracentrifugation and before capturing by 10X Genomics confirming DAPI nuclear 
counterstaining with presence of smaller and larger DAPI+ nuclei. Note that larger nuclei are 
co-stained with anti-NeuN antibody confirming neuronal origin (white arrowheads). (b) 
Colored t-SNE plots showing numbers of genes (left) and UMIs (right) per captured nuclei 
from control and MS samples. (c) Colored t-SNE plot visualizing nuclei from different 
lesion stages based on classic pathological MS lesion staging. (d) Colored t-SNE plots 
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visualizing nuclei from samples with different levels of upper and deep layer cortical 
demyelination as well as subcortical demyelination. (e) Representative tSNE plots with cell-
type specific marker genes for OL progenitor cells, stromal cells including pericytes, 
endothelial cells, and leukocytes. For tSNE plots, data shown from 9 control and 12 MS 
samples and a total of 48,919 nuclei.
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Extended Data Fig. 2. Molecular changes in cortical neuron subtypes in MS lesions.
(a) NORAD and PPIA expression patterns in cortical neurons and selected glial subtypes. 
Note baseline expression of NORAD and PPIA in neuronal versus glial subtypes and 
preferential upregulation of both NORAD and PPIA in upper cortical layer excitatory 
neurons (EN-L2-3 and EN-L4) in MS lesion tissue versus deep cortical layer excitatory and 
inhibitory neurons (EN-L5-6 and IN-SST). For all tSNE and violin plots, data are shown 
from 9 control and 12 MS samples. For tSNE plots, data from 48,919 nuclei are shown. For 
EN-L2-3, EN-L4 and EN-L5-6 violin plots, data shown from 6,120, 3,125 and 3,058 nuclei. 
Box plots inside violin plots represent median and standard deviation of gene expression. (b) 
Visualization of enriched GO terms in EN-L2-3, EN-L4 and EN-L5-6 cells based on 
differential gene expression analysis (linear mixed model regression). Binomial test with 
FDR correction was utilized to calculate FDR-corrected p values using genes differentially 
expressed in EN-L2-3, EN-L4 and EN-L5-6 nuclei (n= 428, 364 and 327).
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Extended Data Fig. 3. Cortical neuron and lymphocyte subtype analysis in MS lesions.
(a) tSNE plots for neuron subtype specific expression of RORB, THY1, NRGN, SST, SV2C 
and PVALB (left). LaST (ctrl, n= 5) showing layer-specific expression of neuronal RORB in 
intermediate cortical layer 4 and widespread expression of pyramidal neuron marker THY1 
with enrichment in layer 5; note that SST-expressing interneurons preferentially map to deep 
cortical layers. Co-expression studies (ctrl, n= 5) with SYT1 confirm neuronal expression of 
RORB, THY1 and SST (black arrowheads). (b) Heatmap with hierarchical clustering of 
lymphocyte-associated transcripts allowing sub clustering of lymphocytes in T cells, B cells 
and plasma cells based on marker gene expression (upper left). tSNE plots for typical B/
plasma cell and T cell marker genes enriched in lymphocyte clusters (upper right). IHC for T 
cell marker SKAP1 (black arrowheads mark SKAP1+ T cells) together with spatial 
transcriptomics for B cell-associated IGHG1 encoding immunoglobulin G1 (IgG1) 
(magenta-colored arrowheads; lower left); note preferential clustering of plasma cell-
associated MZB1+ and IGHG1-expressing B cells (white arrowheads, lower right) in 
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inflamed meningeal tissue versus mixed T and B cell infiltration in perivascular cuffs of 
subcortical lesions (lower panels). One caveat to these findings is the relatively small 
number of MS cases samples, which limited our ability to cluster T cell populations. For 
tSNE plots (a, b) and hierarchical clustering (b), data shown from 9 control and 12 MS 
samples. For tSNE plots, data shown for all 48,919 nuclei; for hierarchical clustering, data 
shown from 53 nuclei in the B cell cluster. For ISH and IHC experiments in b, representative 
images shown from individual tissue sections (ctrl, n= 4; MS, n= 7).
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Extended Data Fig. 4. Astrocyte and oligodendrocyte cluster analysis and spatial transcriptomics 
in MS lesions.
(a) Differential spatial expression patterns of astroglial GFAP in subcortical versus cortical 
demyelination by IHC (left); tSNE plots visualizing astrocyte specific genes corresponding 
to all (RFX4) protoplasmic (SLC1A2, GPC5) and fibrous/reactive astrocytes (GFAP, 
CD44). Quantification of RFX4+ ISH signals per nuclei in GM and WM of control samples 
validates RFX4 as a canonical astrocyte marker (ctrl, n= 5); quantification of GPC5+ and 
CD44+ ISH signals per RFX4+ astrocytes confirms validates GPC5 as protoplasmic GM and 
CD44 as fibrous WM marker. Two-tailed Mann-Whitney tests were performed. Data 
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presented as mean ± SEM. (b) Upregulation of astroglial CRYAB, MT3 (black arrowheads) 
and endothelin type B receptor transcript EDNRB (white arrowhead) in reactive astrocytes 
in subcortical lesions. (c) tSNE plots showing OL-specific expression of myelin genes MBP, 
CNP and transcription factor ST18; note co-expression of ST18 with PLP in control WM by 
ISH. (d) Visualization of enriched GO terms in myelinating OLs based on differential gene 
expression analysis. Binomial test with FDR correction was utilized to calculate FDR-
corrected p values using 151 genes differentially expressed in OLs. (e) Co-expression spatial 
transcriptomic studies confirming upregulation of heat shock protein 90 transcript 
HSP90AA1 in both progenitor (PDGFRA-expressing) and myelinating (PLP1-expressing) 
OLs at lesion rims (PPWM, black arrowheads). For tSNE and violin plots, data shown from 
9 control and 12 MS samples. For astrocyte violin plots, 1,571 control and 3,810 MS nuclei 
are shown. Box plots inside violin plots represent median and standard deviation of gene 
expression. For ISH and IHC experiments, representative images from from 3 control and 4 
MS individual tissue sections are shown.
Schirmer et al. Page 26
Nature. Author manuscript; available in PMC 2020 January 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended Data Fig. 5. Cluster analysis of activated and phagocytosing microglia subtypes.
Hierarchical cluster analysis identifies several homeostatic and activated MS-specific 
microglia subtypes according to inflammatory lesion stages allowing transcriptomic staging 
of microglia subtypes. Clusters with enriched genes are marked and annotated a-f (see 
Supplementary Table 8 for gene list). Note that phagocytosing cells are identified by 
presence of OL/myelin genes (cluster “f” on bottom of heatmap).
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Extended Data Fig. 6. PCR for rat Mbp from myelin preparation.
(a) Representative Coomassie stain of brain homogenate (Hom.) and purified myelin (P.M.) 
from adult rat brain (left). Western blots for myelin basic protein (Mbp), myelin 
oligodendrocyte glycoprotein (Mog), synaptophysin (Syp) and neurofilament heavy 
molecular weight (NF-H) (center). PCRs of myelin basic protein (Mbp) and synaptophysin 
(Syp) transcripts in brain homogenate and purified myelin fractions (right). (b) 
Densitometric quantification of myelin and homogenates prepared from n= 4 independent 
rat hemispheres for Coomassie (total protein), Western blot proteins and PCRs shown in (a) 
of purified myelin fractions normalized to their respective homogenates. Data is shown as 
median and error bars ± standard error of the mean of the 4 biological replicates. Similar 
results were obtained with Hom. and P.M. fractions not used in this study. P values 
calculated from Students’s two tailed t-test with Welch's correction and p values less than 
0.05 considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Experimental approach and characteristics of snRNA-seq using frozen MS tissue.
(a) Cortical and subcortical control tissue and MS lesion types (DM = demyelination, NA = 
normal appearing). (b) Experimental approach for isolating nuclei from postmortem snap-
frozen brain samples of MS and control patients. (c) Cell types from individual samples 
(left), cell-type specific clusters (center; ctrl, n= 9; MS, n= 12) and sample contribution to 
individual clusters (right). Note separation of EN-L2-3 and OL cells into MS-specific 
clusters EN-L2-3-A/B and OL-B/C. (d) tSNE plots highlight marker genes for neurons, 
astrocytes, OLs and microglia. (e) Bar chart shows contributions of normalized control and 
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MS cell numbers to major cell-type clusters. Note that EN-L2-3-A cell enrichment and 
concomitant decrease in EN-L2-3-B in control samples over MS was not statistically 
significant (p = 0.165 and 0.082). (f) Specific loss of EN-L2-3 versus EN-L4, EN-L5-6 or 
IN-VIP neurons based on normalized cell numbers. (g) Differential gene expression (DGE) 
analysis showing highest number of dysregulated genes in EN-L2-3 followed by EN-L4 and 
OL cells; least differentially expressed genes were found in SST INs and OPCs. Box plots 
represent median and interquartile range (IQR) of differentially expressed gene number 
calculated after downsampling (100 DGE analyses per cell cluster; ctrl, n= 9; n= 12 MS). 
Wiskers extend to the largest values within 1.5 IQR from box boundaries, outliers shown as 
dots, notches represent a 95% confidence interval around the median. Two-tailed Mann-
Whitney tests performed in e and f (ctrl, n= 9; MS, n= 12); *P ≤ 0.05. Data presented as 
mean ± SEM. For tSNE plots, data shown from a total of 48,919 nuclei (ctrl, n= 9; n= 12 
MS).
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Fig. 2. Pseudotime trajectory analysis of upper layer excitatory projection neurons.
(a) Trajectory analysis of CUX2-expressing EN-L2-3 cells (upper left). Unsupervised 
pseudotime trajectories within the EN-L2-3 (upper right) cluster reflected cellular origin 
from MS samples or controls (lower left) and inflammatory lesion stage (lower right). (b) 
EN-L2-3 pseudotime trajectories showed similar features as (a) and suggested loss of 
normalized EN-L2-3 numbers (lower left). Strongest association with EN-L2-3 trajectories 
found for upper cortical layer demyelination (upper right) versus deep cortical layer (center 
right) and subcortical demyelination (lower right). (c) Note selective enrichment of 
dysregulated genes in EN-L2-3 cells from samples with late chronic inactive lesions versus 
acute/chronic-active and control samples. (d) Visualization of GO terms (enrichment 
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calculated using GSEA, FDR adjusted p ≤ 0.05, no terms significantly decreased) in genes 
significantly regulated in EN-L2-3 in a pseudotime-dependent manner (Moran’s I test, FDR 
adjusted p ≤ 0.0001). Note enrichment of severe cell stress processes. (e) Trajectory-
dependent upregulated (f) and downregulated EN-L2-3 genes of interest. Grey shading 
represent 95% confidence interval based on gene expression in all (n= 5,938) sampled EN-
L2-3 nuclei.
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Fig. 3. Cellular and molecular neuronal pathology in cortical MS lesions.
(a) tSNE plots CUX2, VIP and TLE4-expressing neurons (left). Spatial transcriptomics 
showing layer-specific expression of CUX2 in lesion (indicated by loss of MOG) versus 
non-lesion areas (center left). Schematic illustrates layer-specific neuron subtype diversity 
(center). Note CUX2 and VIP expression in upper and TLE4 in deep cortical layers by 
smFISH (center right; ctrl, n=5), and validation of neuronal expression by SYT1 ISH (black 
arrowheads; ctrl, n=5). (b) CUX2 and VIP smFISH demonstrate reduction of CUX2- but not 
VIP-expressing upper layer neurons in DMGM underlying meningeal inflammation (upper 
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left and right) versus incomplete demyelinated (IDMGM), NAGM and control cortical GM 
(bottom left). ANOVA with Kruskal Wallis multiple comparison tests were performed (ctrl, 
n=5 (CUX2), n=4 (VIP); MS, n=8; *P ≤ 0.05; different samples with NAWM, IDMGM and 
DMGM MS lesion areas from same sections; representative images). (c) Upregulation of 
neuronal PPIA in DMGM and NAGM versus control GM (left, white circles indicate 
perinuclear areas of PPIA quantification). Neuronal upregulation and cytoplasmic 
accumulation of LINC00657 (NORAD) in DMGM versus NAGM and control areas (right, 
black arrowheads). ANOVA with Tukey’s multiple comparison tests were performed (ctrl, 
n=3; MS, n=4; **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001; different samples with NAWM 
and DMGM areas from same sections; representative images). Data presented as mean ± 
SEM. For tSNE plots, data shown from a total of 48,919 nuclei (ctrl, n = 9; n = 12 MS). 
Violin plots represent DGE (normalized log transformed UMIs) in EN-L2-3 (EN-L2-3-A 
and EN-L2-3-B) nuclei (ctrl, n = 3,481; n = 2,639 MS); box plots represent median and 
standard deviation of gene expression.
Schirmer et al. Page 37
Nature. Author manuscript; available in PMC 2020 January 17.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Fig. 4. Transcriptomic changes in astrocytes and myelinating oligodendrocytes in cortical and 
subcortical MS lesions.
(a) Downregulation of SLC1A2 and GPC5 and upregulation of GFAP and CD44 in MS 
astrocytes (upper left). LaST ISH experiments confirm SLC1A2 downregulation in DMGM 
underlying meningeal inflammation, whereas CD44 shows ubiquitous expression in NAWM 
and PPWM (periplaque white matter, center left) and upregulation in reactive astrocytes at 
lesion rims in b1 (center right). Note CD44 and GPC5 co-expression with pan-astrocyte 
marker RFX4 (white/black arrowheads, lower left and right) and association of CD44 with 
fibrous/reactive WM astrocytes and GPC5 with protoplasmic cortical GM astrocytes (black 
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arrowheads; right; white star indicates blood vessel). (b) Downregulation of GLUL and 
KCNJ10 in MS astrocytes (left). Note differential upregulation of BCL6 and FOS in reactive 
astrocytes at PPWM (center, black arrowheads) and LINC01088 in fibrous/reactive WM 
astrocytes (right, black arrowhead). (c) Violin plots for selected genes linked to cell stress 
(upregulated, top), myelin biosynthesis and axon maintenance (downregulated, bottom) in 
MS OLs. (d) FTL and FTH1 upregulation in PLP1-expressing OLs at iron-laden lesions 
rims (left, black arrowheads). Note differential upregulation of B2M and HLA-C in PLP1-
expressing OLs at PPWM (right; yellow arrowheads [white arrowheads mark OLs without 
B2M ISH signals in NAWM]). For ISH, representative images shown (ctrl, n = 3; n = 4 MS). 
For tSNE plots, data shown from a total of 48,919 nuclei (ctrl, n = 9; n = 12 MS). Violin 
plots represent DGE (normalized log transformed UMIs) in nuclei (astrocytes: ctrl, n = 
1,571; n = 3,810 MS; OLs [OL-A, OL-B and OL-C]: ctrl, n = 3,070; n = 9,324 MS;); box 
plots represent median and standard deviation of gene expression.
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Fig. 5. Transcriptomic changes in activated and phagocytosing microglia subsets.
(a) Violin and tSNE plots for upregulated genes in MS microglia linked to myelin 
phagocytosis/breakdown (left), microglia activation and iron handling (center); note 
downregulation of genes encoding for synapse function (SYNDIG1) and potassium 
homeostasis (KCNQ3) (right). (b) Pseudo low resolution 3D rendering of confocal images 
showing subcortical WM lesions of different inflammatory stages by MBP smFISH and 
CD68 IHC; white arrowheads indicate CD68+ cells with MBP+ ISH signals; note 
colocalization of MBP, CD74 and RUNX1 in CD68-positive cells (center left, white 
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arrowheads). CD68 IHC identifies WM lesion (blood vessel, black star; upper right) with 
upregulation of MSR1 at lesion rims, co-expressed with RUNX1 (lower right) and FTL 
(upper right, black arrowheads); representative images from different tissue sections (ctrl, 
n=3; MS, n=4). (c) Human (upper left; n=3 individual biopsies) and mouse (upper center 
right; n=4 independent cultures) myelin-microglia engulfment assays confirming ingestion 
of MBP and PLP1 transcripts derived from rat myelin. Note localization to nuclear/
perinuclear spaces (white arrowheads). Microglia labeled by pHrodo (human) and Iba1/
CD68 (mouse) with LMNA/C and DAPI nuclear counterstain. Schematic illustrates myelin 
phagocytosis and uptake into microglial (peri-)nuclear spaces (upper right). MBP 
persistence up to 4 days after ingestion in mouse microglia as shown by smFISH (4 
independent cultures; lower left); note upregulation of Cd163 and downregulation of P2ry12 
in phagocytosing mouse (6 independent cultures) and human MS microglia (lower right). 
Two-tailed Mann-Whitney tests performed. Data presented as mean ± SEM. For tSNE plots, 
data shown from a total of 48,919 nuclei (ctrl, n = 9; n = 12 MS). Violin plots represent 
DGE (normalized log transformed UMIs) in microglia nuclei (ctrl, n = 159; n = 1,524 MS 
[microglial and phagocytosing cells]); box plots represent median and standard deviation of 
gene expression.
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